📗 Cite This Artifact
Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP
Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP</th>
</tr>
<tr>
<td class="label">Node Category</td>
<td>Target Proteins</td>
</tr>
<tr>
<td class="label">Tau pathology</td>
<td>pTau181, MTBR-tau, oligomers</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>TREM2, CSF1R, IL-1β, IL-6, TNF-α</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>NRF2, GPX4, SOD, catalase</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>mTOR, TFEB, PINK1, LC3</td>
</tr>
<tr>
<td class="label">Synaptic function</td>
<td>BDNF, NMDA, AMPA, GABA</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>Peak concentration</td>
</tr>
<tr>
<td class="label">AUC</td>
<td>Total exposure</td>
</tr>
<tr>
<td class="label">Cmin</td>
<td>Trough level</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>Elimination rate</td>
</tr>
<tr>
<td class="label">Drug A</td>
<td>Drug B</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Warfarin</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>NACET</td>
</tr>
<tr>
Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP</th>
</tr>
<tr>
<td class="label">Node Category</td>
<td>Target Proteins</td>
</tr>
<tr>
<td class="label">Tau pathology</td>
<td>pTau181, MTBR-tau, oligomers</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>TREM2, CSF1R, IL-1β, IL-6, TNF-α</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>NRF2, GPX4, SOD, catalase</td>
</tr>
<tr>
<td class="label">Autophagy</td>
<td>mTOR, TFEB, PINK1, LC3</td>
</tr>
<tr>
<td class="label">Synaptic function</td>
<td>BDNF, NMDA, AMPA, GABA</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>Peak concentration</td>
</tr>
<tr>
<td class="label">AUC</td>
<td>Total exposure</td>
</tr>
<tr>
<td class="label">Cmin</td>
<td>Trough level</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>Elimination rate</td>
</tr>
<tr>
<td class="label">Drug A</td>
<td>Drug B</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Warfarin</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Metformin</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>NACET</td>
</tr>
<tr>
<td class="label">GLP-1 agonist</td>
<td>NRL2 activator</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>CYP Inhibitor</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>None</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>None</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Weak 2D6</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>Moderate 2D6</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>None</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Risk</td>
</tr>
<tr>
<td class="label">Rasagiline + Lithium</td>
<td>Serotonin syndrome</td>
</tr>
<tr>
<td class="label">Rasagiline + Tramadol</td>
<td>Serotonin syndrome</td>
</tr>
<tr>
<td class="label">Rasagiline + Dextromethorphan</td>
<td>Serotonin syndrome</td>
</tr>
<tr>
<td class="label">Donepezil + Memantine</td>
<td>Cognitive enhancement</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">NCT05297202</td>
<td>Lithium + riluzole</td>
</tr>
<tr>
<td class="label">NCT06038879</td>
<td>CoQ10 + Vitamin D</td>
</tr>
<tr>
<td class="label">NCT05515315</td>
<td>GLP-1 + Exercise</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">1</td>
<td>CoQ10 + Sulforaphane</td>
</tr>
<tr>
<td class="label">2</td>
<td>GLP-1 agonist + Exercise</td>
</tr>
<tr>
<td class="label">3</td>
<td>Donepezil + Memantine</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rapamycin + Trehalose</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Current Dose</td>
</tr>
<tr>
<td class="label">Levodopa/Carbidopa</td>
<td>Per neurology</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>1 mg</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Starting Dose</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>100 mg BID</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>50 mg daily</td>
</tr>
<tr>
<td class="label">Vitamin D3</td>
<td>2000 IU</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>✓</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MDS-UPDRS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">PSPRS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Scientific Rationale</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical Readiness</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Patient Personalization</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>36/50</td>
</tr>
</table>
Computational pharmacology leverages artificial intelligence, machine learning, and network analysis to optimize multi-target drug combinations for complex neurodegenerative diseases like CBS/PSP.[@j2024] This approach addresses the fundamental challenge of treating tauopathies: multiple pathological pathways must be targeted simultaneously for meaningful disease modification.
Rationale for Computational Approaches in CBS/PSP
CBS/PSP involve convergent pathological mechanisms that require multi-target interventions:
- Tau pathology: Aggregation, spreading, post-translational modifications
- Neuroinflammation: Microglial activation, cytokine networks, complement
- Oxidative stress: Mitochondrial dysfunction, ROS accumulation
- Protein clearance: Autophagy-lysosome impairment, glymphatic dysfunction
- Synaptic loss: Dendritic spine degeneration, neurotransmitter deficits
- Metal dysregulation: Iron, copper, zinc homeostasis disruption
Traditional drug development treats each pathway as a separate target. Computational pharmacology integrates these pathways into network models that predict synergistic combinations.[@j2024]
Network Pharmacology Framework
Multi-Target Drug Network Analysis
Network pharmacology identifies drugs that modulate multiple disease-relevant nodes simultaneously:
Key Network Nodes for CBS/PSP
AI-Driven Drug Combination Design
Machine Learning Models for Combination Prediction
1. Synergy Prediction Models
Training Data Sources:
- Cancer cell line synergy screens (ALMANAC, O'Neil)
- PD patient-derived neuron responses
- Preclinical tauopathy models (iPSC neurons, organoids)
- Drug physicochemical properties (Morgan fingerprints)
- Gene expression signatures
- Protein-protein interaction networks
- Pathway activity scores
- DeepSynergy: CNN with drug pair embeddings
- DeepCompo: Graph neural networks for pathway integration
- TranSynergy: Transformer-based sequence modeling
2. Patient-Specific Optimization
Personalized Combination Design:
- Whole genome sequencing (MAPT, GBA, APOE variants)
- Transcriptomics (iPSC neuron gene expression)
- Metabolomics (NAD+, glutathione, lactate)
- Proteomics (NfL, p-tau217, GFAP)
- Patient-specific iPSC neuron networks
- Tauopathy pathway models
- Drug-target interaction mapping
- Reinforcement learning for combination generation
- Multi-objective optimization (efficacy, safety, drug interactions)
- Simulated annealing for dose optimization
Dosing Optimization Algorithms
Pharmacokinetic/Pharmacodynamic Modeling
Compartmental Models:
PK/PD Integration:
- Population PK modeling for CBS/PSP patients
- Disease progression models (UPDRS, PSPRS trajectories)
- Bayesian adaptive dosing based on biomarker response
Combination Dosing Optimization
Algorithm: Multi-Objective Optimization
Objective Function:
- Maximize: Tau reduction (p-tau217), Neuroprotection (NfL trajectory)
- Minimize: Adverse effects, Drug interaction risk
- Constraints: Maximum daily doses, Drug compatibility
Variables:
- Drug doses (continuous)
- Dosing frequency (categorical)
- Treatment duration (discrete)
Methods:
- NSGA-II (Pareto-optimal combinations)
- Bayesian optimization (efficient sampling)
- Reinforcement learning (sequential dose adjustment)
Drug Interaction Matrices
Pharmacodynamic Interactions
Pharmacokinetic Interactions
CYP450 Enzyme Effects
Contraindicated Combinations
Combination Therapy Trials in CBS/PSP
Active and Recent Trials
Trial Design Considerations
1. Combination vs Monotherapy
Factorial Design:
Placebo Drug A Drug B Drug A + Drug B
Group 1 + - - -
Group 2 - + - -
Group 3 - - + -
Group 4 - + + -
Advantages:
- Additive, synergistic, or antagonistic effects detected
- Smaller sample size than multiple monotherapy trials
- Interaction effects characterized
2. Adaptive Platform Trials
Features:
- Multiple arms with drug combinations
- Interim analyses for arm dropping/adding
- Bayesian response-adaptive randomization
- Biomarker-stratified randomization
- Master protocol with multiple塔
- Initial arms: monotherapies
- Expansion arms: synergistic combinations
- Biomarker-guided arm selection
Computational Pipeline for CBS/PSP
Step-by-Step Protocol
Step 1: Patient Characterization
- MAPT (H1/H2 haplotype, mutations)
- GBA (carrier status, variants)
- APOE (ε2/ε3/ε4 genotype)
- LRRK2, C9orf72, GRN
- Blood: NfL, p-tau217, GFAP
- CSF: t-tau, p-tau181, α-synuclein
- Imaging: MRI, Tau PET, FDG-PET
- MDS-UPDRS, PSPRS, MoCA
- Disease duration, symptom onset
Step 2: Network Model Construction
- KEGG pathway mapping
- Protein-protein interactions
- Gene-disease associations
- Binding affinity databases (ChEMBL, DrugBank)
- Transcriptomic signatures (LINCS)
- Phenotypic screens
- Genetic variants mapped to network
- Biomarker levels as node weights
Step 3: AI Combination Generation
- Graph neural network for drug pairs
- Reinforcement learning for combinations
- Knowledge-based filtering
- Deep learning synergy scores
- Pathway enrichment analysis
- Literature mining
- Multi-objective optimization
- PK/PD constraint satisfaction
- Safety filtering
Step 4: Clinical Translation
- Mechanistic strength (1-10)
- Clinical evidence level (1-10)
- Safety profile (1-10)
- Dosing schedule
- Monitoring plan
- Stopping rules
- Pharmacy coordination
- Patient consent
- Outcome tracking
CBS/PSP Patient-Specific Protocol
Current Regimen Analysis
Patient Profile:
- 50-year-old male
- Alpha-synuclein negative (a-syn negative)
- DAT scan: dopamine neuron loss confirmed
- Current medications: levodopa, rasagiline (MAO-B inhibitor)
Computational Optimization Results
Recommended Combinations
Dosing Optimization
Current Regimen:
Recommended Additions:
Monitoring Protocol
NET Assessment
Patient Action Items
Cross-Links
- [Multi-Target Combination Therapy](/therapeutics/combination-therapy-multi-target-cbs-psp) — General combination strategies
- [Combination Therapy Synergies](/therapeutics/combination-therapy-cbs-psp) — Synergistic pairs and protocols
- [Network Pharmacology in Neurodegeneration](/mechanisms/network-pharmacology-neurodegeneration) — Network analysis methods
- [iPSC Drug Screening](/therapeutics/ipsc-neurons-drug-screening-cbs-psp) — Patient-specific drug testing
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
- [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
- [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
- [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
Related Analyses:
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-section-199-computational-pharmacology-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-c43124e73f51 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-199-computational-pharmacology-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-section-199-computational-pharmacology-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Computational Pharmacology and AI-Driven Drug Combination Optimization for CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-section-199-computational-pharmacology-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-section-199-computational-pharmacology-cbs-psp